Compare · NTRA vs YDES
NTRA vs YDES
Side-by-side comparison of Natera Inc. (NTRA) and YD Bio Limited (YDES): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTRA and YDES operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $30.34B, about 118.7x YDES ($255.7M).
- Over the past year, NTRA is up 26.7% and YDES is down 73.1% - NTRA leads by 99.8 points.
- NTRA has been more active in the news (13 items in the past 4 weeks vs 2 for YDES).
- NTRA has more recent analyst coverage (25 ratings vs 0 for YDES).
- Company
- Natera Inc.
- YD Bio Limited
- Price
- $211.96-0.36%
- $3.60+22.45%
- Market cap
- $30.34B
- $255.7M
- 1M return
- +0.14%
- -28.43%
- 1Y return
- +26.70%
- -73.05%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 13
- 2
- Recent ratings
- 25
- 0
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest NTRA
- Director Botha Roelof sold $17,184,092 worth of shares (78,000 units at $220.31) (SEC Form 4)
- Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors
- Wolfe Research resumed coverage on Natera with a new price target
- SEC Form 144 filed by Natera Inc.
- Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $335,091 worth of shares (1,652 units at $202.84) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 140,643 units (SEC Form 4) to satisfy withholding obligation
- PRESIDENT, CHIEF BUS. OFFICER Fesko John sold $291,684 worth of shares (1,438 units at $202.84) as part of a pre-agreed trading plan, decreasing direct ownership by 0.77% to 185,782 units (SEC Form 4) (withholding tax)
- Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer
- Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology
- Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology
Latest YDES
- SEC Form EFFECT filed by YD Bio Limited
- SEC Form POS AM filed by YD Bio Limited
- YD Bio Limited Reports Full Year 2025 Financial Results
- SEC Form 20-F filed by YD Bio Limited
- Amendment: SEC Form 3 filed by new insider Lu Shao-Ta
- SEC Form 4 filed by Lu Shao-Ta
- SEC Form 4 filed by Chang Kochi
- SEC Form 3 filed by new insider Lu Shao-Ta
- SEC Form 3 filed by new insider Chang Kochi
- YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States